HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mark Ratner

Latest From Mark Ratner

Science Matters: Welcome To The Oncobiome

A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.

Innovation Research and Development Strategies

Science Matters: Targeting Heme Trafficking In A Variety Of Diseases

A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.

Research and Development Strategies Research & Development

Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot

A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.

Research and Development Strategies Cancer

Science Matters: Glimmers Of Hope For Treating ALS

Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.

Innovation Rare Diseases

Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom

No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view. 

Innovation Research and Development Strategies

Pharma’s Digital Directive: Not If, But How

Data science and data analytics offer operational advantages throughout large organizations. And the pharma should approach digital technology pragmatically, first applying the tools to what it already does.

Digital Health Innovation
See All
UsernamePublicRestriction

Register